Literature DB >> 32845402

Promising and Upcoming Treatments in Myositis.

Lauren N Smith1, Julie J Paik2.   

Abstract

PURPOSE OF REVIEW: To highlight new and emerging treatment targets in myositis. RECENT
FINDINGS: The landscape of novel therapeutics in myositis has vastly changed in the past 5 years. This is largely due to a greater understanding of the pathogenesis of myositis and validation of more robust outcome measures that standardize the ability to assess treatment response. Clinical trials in dermatomyositis are leading the way with ongoing multicenter, international phase 3 clinical trials. Proof-of-concept studies targeting the JAK/STAT pathway have also showed early promise in treating refractory dermatomyositis in adults and children. This review highlights that the future armamentarium of therapeutic drugs will likely be larger and more selective in treating different subgroups of myositis.

Entities:  

Keywords:  Dermatomyositis; Immune-mediated necrotizing myopathy; Myositis; Novel treatments

Year:  2020        PMID： 32845402      PMCID： PMC7955788          DOI： 10.1007/s11926-020-00943-2

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


  50 in total

1.  Remission of recalcitrant dermatomyositis treated with ruxolitinib.

Authors:  Thorsten Hornung; Viktor Janzen; Franz-Josef Heidgen; Dominik Wolf; Thomas Bieber; Joerg Wenzel
Journal:  N Engl J Med       Date:  2014-12-25       Impact factor: 91.245

2.  Reversal of chronic polymyositis following intravenous immune serum globulin therapy.

Authors:  C M Roifman; F M Schaffer; S E Wachsmuth; G Murphy; E W Gelfand
Journal:  JAMA       Date:  1987 Jul 24-31       Impact factor: 56.272

Review 3.  Cannabinoids and autoimmune diseases: A systematic review.

Authors:  Valeria Katchan; Paula David; Yehuda Shoenfeld
Journal:  Autoimmun Rev       Date:  2016-02-11       Impact factor: 9.754

4.  Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.

Authors:  Michael G Hanna; Umesh A Badrising; Olivier Benveniste; Thomas E Lloyd; Merrilee Needham; Hector Chinoy; Masashi Aoki; Pedro M Machado; Christina Liang; Katrina A Reardon; Marianne de Visser; Dana P Ascherman; Richard J Barohn; Mazen M Dimachkie; James A L Miller; John T Kissel; Björn Oskarsson; Nanette C Joyce; Peter Van den Bergh; Jonathan Baets; Jan L De Bleecker; Chafic Karam; William S David; Massimiliano Mirabella; Sharon P Nations; Hans H Jung; Elena Pegoraro; Lorenzo Maggi; Carmelo Rodolico; Massimiliano Filosto; Aziz I Shaibani; Kumaraswamy Sivakumar; Namita A Goyal; Madoka Mori-Yoshimura; Satoshi Yamashita; Naoki Suzuki; Masahisa Katsuno; Kenya Murata; Hiroyuki Nodera; Ichizo Nishino; Carla D Romano; Valerie S L Williams; John Vissing; Lixin Zhang Auberson; Min Wu; Ana de Vera; Dimitris A Papanicolaou; Anthony A Amato
Journal:  Lancet Neurol       Date:  2019-09       Impact factor: 44.182

Review 5.  Classification and management of adult inflammatory myopathies.

Authors:  Albert Selva-O'Callaghan; Iago Pinal-Fernandez; Ernesto Trallero-Araguás; José César Milisenda; Josep Maria Grau-Junyent; Andrew L Mammen
Journal:  Lancet Neurol       Date:  2018-09       Impact factor: 44.182

Review 6.  International consensus on preliminary definitions of improvement in adult and juvenile myositis.

Authors:  Lisa G Rider; Edward H Giannini; Hermine I Brunner; Nicola Ruperto; Laura James-Newton; Ann M Reed; Peter A Lachenbruch; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2004-07

7.  Targeting protein homeostasis in sporadic inclusion body myositis.

Authors:  Mhoriam Ahmed; Pedro M Machado; Adrian Miller; Charlotte Spicer; Laura Herbelin; Jianghua He; Janelle Noel; Yunxia Wang; April L McVey; Mamatha Pasnoor; Philip Gallagher; Jeffrey Statland; Ching-Hua Lu; Bernadett Kalmar; Stefen Brady; Huma Sethi; George Samandouras; Matt Parton; Janice L Holton; Anne Weston; Lucy Collinson; J Paul Taylor; Giampietro Schiavo; Michael G Hanna; Richard J Barohn; Mazen M Dimachkie; Linda Greensmith
Journal:  Sci Transl Med       Date:  2016-03-23       Impact factor: 17.956

8.  Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial.

Authors:  Nobuyuki Miyasaka; Masako Hara; Takao Koike; Eizo Saito; Masahito Yamada; Yoshiya Tanaka
Journal:  Mod Rheumatol       Date:  2011-10-05       Impact factor: 3.023

9.  Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia.

Authors:  Takuya Kotani; Tohru Takeuchi; Shigeki Makino; Kenichiro Hata; Shuzo Yoshida; Koji Nagai; Daisuke Wakura; Takeshi Shoda; Toshiaki Hanafusa
Journal:  Clin Rheumatol       Date:  2011-02-23       Impact factor: 3.650

10.  Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.

Authors:  Charalampia Papadopoulou; Ying Hong; Ebun Omoyinmi; Paul A Brogan; Despina Eleftheriou
Journal:  Brain       Date:  2019-03-01       Impact factor: 13.501
View more
  2 in total

Review 1.  Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases.

Authors:  Hideyuki Ujiie; David Rosmarin; Michael P Schön; Sonja Ständer; Katharina Boch; Martin Metz; Marcus Maurer; Diamant Thaci; Enno Schmidt; Connor Cole; Kyle T Amber; Dario Didona; Michael Hertl; Andreas Recke; Hanna Graßhoff; Alexander Hackel; Anja Schumann; Gabriela Riemekasten; Katja Bieber; Gant Sprow; Joshua Dan; Detlef Zillikens; Tanya Sezin; Angela M Christiano; Kerstin Wolk; Robert Sabat; Khalaf Kridin; Victoria P Werth; Ralf J Ludwig
Journal:  Front Med (Lausanne)       Date:  2022-06-09

Review 2.  A glance into the future of myositis therapy.

Authors:  Ilaria Chiapparoli; Claudio Galluzzo; Carlo Salvarani; Nicolò Pipitone
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-05-24       Impact factor: 3.625
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.